NCT05575505

Phosphodiesterase Inhibitors, Pentoxifylline, as Adjunctive Therapy in Patients With Ulcerative Colitis.

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 44 (estimated)
• Sponsor: Tanta University · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Ulcerative colitis (UC) is an idiopathic, chronic inflammatory disease characterized by diffused inflammation of the colon and rectum mucosa; however, the exact underlying mechanisms of UC remain poorly understood. Also, it is associated with high risk of colon cancer, so there is a continuous need for introducing new therapies that decrease progression, and hence better outcomes

Conditions

• Inflammatory Bowel Diseases

Interventions

Type	Name	Description
DRUG	Pentoxifylline 400 MG	Pentoxifylline (PTX) is a methyl-xanthine derivative that possesses antioxidant and anti-inflammatory characteristics

Timeline

• Start date: 2023-02-02
• Primary completion: 2026-02-01
• Completion: 2026-02-01
• First posted: 2022-10-12
• Last updated: 2025-03-04

Locations

1 site across 1 country: Egypt